Cohort Profile: The St. Jude Lifetime Cohort Study (SJLIFE) for paediatric cancer survivors
Abstract
Cohort Profile: The St. Jude Lifetime Cohort Study (SJLIFE) for paediatric cancer survivors Carrie R Howell , Kari L Bjornard, Kirsten K Ness, Nicole Alberts, Gregory T Armstrong, Nickhill Bhakta, Tara Brinkman, Eric Caron, Wassim Chemaitilly, Daniel M Green, Tim Folse, I-Chan Huang, John L. Jefferies, Sue Kaste, Kevin R Krull, Jennifer Q Lanctot, Daniel A Mulrooney, Geoffrey Neale, Kim E Nichols, Noah D Sabin, Kyla Shelton, Deo Kumar Srivastava, Zhaoming Wang, Carmen Wilson, Yutaka Yasui, Alia Zaidi, Jinghui Zhang, Leslie L Robison, Melissa M Hudson and Matthew J Ehrhardt * Department of Epidemiology and Cancer Control, St. Jude Children’s Research Hospital, Memphis, TN, USA, Department of Oncology, St. Jude Children’s Research Hospital, Memphis, TN, USA, Department of Psychology, St. Jude Children’s Research Hospital, Memphis, TN, USA, Department of Global Pediatric Medicine, St. Jude Children’s Research Hospital, Memphis, TN, USA, Department of Pediatric Medicine, St. Jude Children’s Research Hospital, Memphis, TN, USA, Division of Adult Cardiovascular Disease, The University of Tennessee Health Science Center, Memphis, TN, USA, Department of Diagnostic Imaging, St. Jude Children’s Research Hospital, Memphis, TN, USA, Hartwell Center, St. Jude Children’s Research Hospital, Memphis, TN, USA, Department of Biostatistics, St. Jude Children’s Research Hospital, Memphis, TN, USA and Department of Computational Biology, St. Jude Children’s Research Hospital, Memphis, TN, USA
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence.
Read the paper
Related studies
- Challenges and opportunities with drug repurposing: finding strategies to find alternative uses of therapeutics
- Challenges in Chagas Disease Drug Development
- T Cell Specificity: A Great Challenge in Chagas Disease
- Benznidazole treatment leads to DNA damage in Trypanosoma cruzi and the persistence of rare widely dispersed non-replicative amastigotes in mice
- Rapid Molecular Detection of Terbinafine-resistant Dermatophytes
- Identifying novel drugs with new modes of action for neglected tropical fungal skin diseases (fungal skinNTDs) using an Open Source Drug discovery approach
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.